InMed Pharmaceuticals Inc (INM)

[lesgetrich]

Eric Ashley Adams, CEO and Director, disposed of 800,000 Common Shares on a direct ownership basis at prices ranging from $1.999 to $2.281 between January 8th, and 9th, 2018. This represents a $1,762,901 divestment of the company's shares and an account share holdings change of -99.0%.

Alexandra Diane Janet Mancini, a Senior Officer, disposed of 40,000 Common Shares on a direct ownership basis at a price of $2.162 on January 8th, 2018. This represents a $86,492 divestment of the company's shares and an account share holdings change of -40.0%.

The reference to "share holdings" only refers to common stock held by each person. It significantly does not include options that were granted to these individuals and the others who took profits this month. The following report published September 12, 2017 shows that all of them continue to hold significant investments in InMed. I've not been able to find any evidence that any of these options were ever converted to common shares...

Form 11 - Notice of Proposed Option Grant